Eloralintide (LY3841136) – 12mg

Eloralintide (LY3841136) is a long-acting synthetic amylin analog studied as a selective amylin receptor agonist. The peptide is conjugated to a C20 fatty diacid moiety enabling reversible albumin binding and an extended plasma half-life consistent with once-weekly subcutaneous administration. In published preclinical work, eloralintide preferentially activates the human amylin 1 receptor (AMY1R), with reported selectivity of approximately 12-fold over the calcitonin receptor (CTR) and 11-fold over AMY3R — a profile differentiating it from non-selective amylin analogs such as cagrilintide. Eloralintide is investigated in research models for receptor pharmacology, food intake regulation, body composition, and gastrointestinal tolerability endpoints.

Benefits (Research Focus)

• Selective AMY1R agonism — studied for preferential activation of amylin 1 receptor over calcitonin and AMY3 receptors

• cAMP signaling — investigated for amylin receptor pharmacology and downstream signal transduction

• Food intake regulation — explored for satiety pathway endpoints in preclinical research

• Body composition research — examined for fat-mass and lean-mass partitioning in DIO models

• GI tolerability profile — researched for conditioned-taste-avoidance and gastrointestinal tolerance endpoints

What Researchers Look At

• Receptor binding affinity and selectivity across AMY1R / AMY3R / CTR

• cAMP activation curves in cell lines expressing amylin receptor subtypes

• Food intake, body weight, and adipose-tissue change in DIO rodent models

• Pharmacokinetics and albumin-binding driven half-life extension

• Comparative endpoints versus cagrilintide and pramlintide

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 12.4 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Eloralintide

• Synonyms: LY3841136; LY-3841136; AMY1176

• Class: Selective amylin receptor agonist (AMY1R-preferring); long-acting amylin analog

• Modification: Lipidated with C20 fatty diacid via γGlu-γGlu linker on a Lys residue; intramolecular methylene bridge between Cys2–Cys7

• Formula / M.W.: C₂₀₁H₃₁₉N₄₉O₆₅S₂, ~4526.10 g/mol

• CAS: 2883634-40-8

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Eloralintide COA — May 15, 2026

• Eloralintide COA — August 5, 2026 – Batch #ELO07-1910